Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial
Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial evaluated the efficacy of Xeljanz for the treatment of psoriatic arthritis in a bid to expand the regulatory approval for the drug.
The trial looked at dosages of tofacitinib in psoriatic arthritis patients who had an inadequate response to at least one conventional synthetic disease-modifying anti rheumatic drug and who were tumour necrosis factor naïve. OPAL Broaden met its primary endpoint of demonstrating superiority to placebo at 3 months.
Michael Corbo, category development lead in inflammation and immunology, comments: “As a chronic inflammatory disease, psoriatic arthritis can have a significant impact on a person’s daily life. Despite available therapies, including biologic and oral treatments, there remains an unmet need for additional options.
“The results seen in the OPAL Broaden study are encouraging as they suggest that tofacitinib may have the potential to offer an additional effective oral option for patients living with psoriatic arthritis. We look forward to sharing detailed results at a future scientific meeting.”
In other Pfizer news, the company has also issued a statement along with Allergan related to their proposed merger. With the US Department of Treasury announcing additional action to curb company inversions, amid speculation that some form of block to the Pfizer-Allergan move may be made, the companies issued the following: “We are conducting a review of the US Department of Treasury’s actions announced today. Prior to completing the review, we won’t speculate on any potential impact.”
Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee …
Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their …